Shopping Cart
- Remove All
- Your shopping cart is currently empty
PKC-IN-1 is an ATP-competitive and reversible conventional PKC enzymes inhibitor (PKCα, PKCβI, PKCβII, PKCθ, PKCγ, PKC mu and PKCε with IC50s of 2.3, 8.1, 7.6, 25.6, 57.5, 314, 808 nM, respectively).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
2 mg | $198 | In Stock | |
5 mg | $347 | 8-10 weeks | |
25 mg | $1,140 | 8-10 weeks | |
50 mg | $1,490 | 8-10 weeks | |
100 mg | $1,990 | 8-10 weeks | |
1 mL x 10 mM (in DMSO) | $383 | 8-10 weeks |
Description | PKC-IN-1 is an ATP-competitive and reversible conventional PKC enzymes inhibitor (PKCα, PKCβI, PKCβII, PKCθ, PKCγ, PKC mu and PKCε with IC50s of 2.3, 8.1, 7.6, 25.6, 57.5, 314, 808 nM, respectively). |
Targets&IC50 | PKCγ (human):57.5 nM, PKCμ (human):314 nM, PKCε (human):808 nM, PKCβI (human):8.1 nM, PKCβ (human):5.3 nM (ki), PKCβII (human):7.6 nM, PKCθ (human):25.6 nM, PKCα (human):10.4 nM (ki), PKCα (human):2.3 nM |
In vitro | PKC-IN-1 is a potent, ATP-competitive, and reversible of conventional PKC enzymes (PKCα, PKCβI, PKCβII, PKCθ, PKCγ, PKC mu and PKCε with Kis of 5.3 and 10.4 nM for human PKCβ and PKCα, and IC50s of 2.3, 8.1, 7.6, 25.6, 57.5, 314, 808 nM, respectively) [1]. |
In vivo | In Lewis rats, PKC-IN-1 dose-dependently and significantly reduces maximum EAE severity and end severity in the autoimmune encephalitis (EAE) model [1]. |
Molecular Weight | 500.61 |
Formula | C25H37FN8O2 |
Cas No. | 1046787-18-1 |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
Solubility Information | DMSO: 25 mg/mL (49.94 mM) | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.